ECOG Performance Status X See Appendix 7. Vital Signs XIncludes body temperature, respiratory rate, as we ll as seated blood pressure and heart rate. Blood pressure, respiratory rate, and he art rate should be measured after the participant has been seated for at least 5 minutes. 12-lead ECG X12-lead electrocardiograms should be recorded af ter the participant has been supine for at least 5 minutes. All screening ECG tests should be performed as a single ECG. Laboratory Tests Laboratory tests listed below must be completed within 2 weeks of Cycle 1Day 1 unless otherwise noted. Chemistry XSee Section 9.4.4 , Table 9.4.4-1 . Includes assessments for sodium, potassium, chloride, total serum calcium, magnesium, carbon dioxide, phosphorus, BUN, creatinine, creatinine kinase, CrCl (screening onl y), fasting glucose (screening only; on-treatment assessments do not require fasting), total protein, albumin, amylase, lipase, CRP, LDH, AST, ALT, total bili rubin, direct bilirubin (reflex only), ALP, GGT (reflex only), and Testosterone (PRC only). CBC with Differential and PlateletsX Urinalysis XUrine to be checked for protein, glucose, blood, l eukocyte esterase, specific gravity, and pH. Microscopic examination of sedi ment if positive for blood, protein, or leukocyte esterase on dipstick. Revised Protocol No.: 04 Date: 31-May-2019 20 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-1: Screening Procedural Outline (CA021002) ProcedureScreening Visit (Day -28 to -1)Day -7 to -3 VisitDay -3 to -1 VisitNotes Thyroid Function Tests X TSH with reflex to free T3 and T4. Serum Tumor Markers XShould be performed for tumor types, included in this study, with known serologic markers (eg, CEA, CA19-9, and PSA) Viral Status XHNSCC and CC only: Sites should submit and do cument prior human papillomavirus (HPV) status within 28 days of do sing. Serology Tests XWithin 28 days of dosing: hepatitis B surface anti gen and hepatitis C antibody (if positive reflex to hepatitis C RNA) or hepatitis C RNA.